Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00489697
Recruitment Status : Completed
First Posted : June 21, 2007
Last Update Posted : January 4, 2017
Information provided by:
University Hospital, Tours

Brief Summary:
Bevacizumab, an anti-angiogenic agent, plus fluorouracil based chemotherapy is considered a new standard for the treatment of metastatic colorectal cancer. Contrast-enhanced ultrasound with gas-encapsulated microbubbles can be used to assess tumour vascularity, particularly hepatic metastases, and may become a useful tool for monitoring anti-angiogenic therapies. The aim of this prospective, multicenter, non-randomized study is to evaluate the usefulness of hepatic contrast-enhanced ultrasound to predict response to bevacizumab based chemotherapy in patient with metastatic colorectal cancer. The primary objective of this study is to compare the functional vascular changes related to bevacizumab based chemotherapy and evaluated by hepatic contrast-enhanced ultrasound with classic RECIST criteria. The secondary objectives are to do a characterization of the pharmacokinetic of bevacizumab, to explore the pharmacodynamic effects of bevacizumab on functional vascular changes of hepatic metastases evaluated by hepatic contrast-enhanced ultrasound and to analyze the possible relationships between treatment efficacy or toxicity and constitutional gene polymorphisms linked to the bevacizumab.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Device: real-time contrast-enhanced ultrasound imaging (CEUS) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Medical and Economical Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases
Study Start Date : January 2007
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: 1 (single arm)
patient with histologically confirmed colorectal tumor treated in first line by a bevacizumab based chemotherapy
Device: real-time contrast-enhanced ultrasound imaging (CEUS)
Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)

Primary Outcome Measures :
  1. functional vascular changes in tumour vascularity of hepatic metastases [ Time Frame: 2 months ]
  2. Pharmacokinetic of bevacizumab between each cure of bevacizumab based chemotherapy [ Time Frame: 2 months ]
  3. ratio cost/benefit of a strategy of therapeutic monitoring by contrast-enhanced ultrasound [ Time Frame: 2 months ]
  4. evaluation of the response to bevacizumab based chemotherapy by RECIST criteria [ Time Frame: 2 months ]

Secondary Outcome Measures :
  1. bevacizumab-related toxicity [ Time Frame: 2 months ]
  2. response duration [ Time Frame: 2 years ]
  3. time to disease progression [ Time Frame: 2 years ]
  4. survival time [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed colorectal tumor
  • first line treatment by a bevacizumab based chemotherapy
  • Target hepatic metastases of size lower than 5 cm and higher than 5 mm detected by conventional ultrasonography and CT or MRI
  • Life expectancy > 2 months
  • OMS status =< 2
  • Major surgery, open biopsy, or significant traumatic injury within 28 days prior to Day 0
  • informed consent signed

Exclusion Criteria:

  • no target hepatic lesion detected by conventional ultrasonography
  • Prior bevacizumab treatment
  • Prior chemotherapy treatment for advanced disease
  • Clinically significant cardiac disease (e.g. myocardial infarction or stroke within 12 months, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure not well controlled with medication, endocarditis and prosthetic valve) and any contraindications in sulphur hexafluoride administration
  • Blood pressure >= 180/110 mmHg
  • Daily and chronic treatment by aspirin or AINS
  • Anticipation of need for major surgical procedure within 7 days prior day 0
  • Urine protein > 1g/24 Hours
  • Any contraindication in enhancing bevacizumab treatment
  • Serious, uncontrolled, concurrent infection(s) or illness(es)
  • pregnant and lactating woman

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00489697

Layout table for location information
Angers, France, 49033
CRLCC, Centre Paul Papin
Angers, France, 49033
CHRU Besancon
Besançon, France, 25000
Hôpital Saint-André, CHRU Bordeaux
Bordeaux, France, 33075
CRLCC, Centre René Gauducheau
Nantes St Herblain, France, 44805
Hôpital Pitié Salpétrière, Assistance Publique Hôpitaux de Paris
Paris, France, 75651
Hôpital Haut-Lévêque
Pessac, France, 33604
Hôpital La Milétrie, CHRU Poitiers
Poitiers, France, 86000
Hôpital Robert Debré, CHRU Reims
Reims, France, 51092
CHU Pontchaillou
Rennes, France, 35033
CRLCC, Centre Eugène Marquis
Rennes, France, 35042
Chru Tours
Tours, France, 37044
Sponsors and Collaborators
University Hospital, Tours
Layout table for investigator information
Principal Investigator: François TRANQUART, Professor Centre Hospitalier de Tours, France
Principal Investigator: Thierry LECOMTE, Doctor Centre Hospitalier de Tours, France
Study Chair: Bruno GIRAUDEAU, Doctor INSERM CIC 2002, Centre Hospitalier de Tours, France
Study Chair: Emmanuel RUSCH, Professor Centre Hospitalier de Tours, France


Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Directrice de la Recherche et des Affaires Médicales, University Hospital Tours Identifier: NCT00489697    
Other Study ID Numbers: INCA06-FT/STIC-AVASTIN
First Posted: June 21, 2007    Key Record Dates
Last Update Posted: January 4, 2017
Last Verified: January 2017
Keywords provided by University Hospital, Tours:
colorectal cancer
hepatic metastases
anti-angiogenic agent
chemotherapy regimens
tumor vascularity
Contrast-enhanced ultrasound
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors